- Published on
Ophthalmology – Conjunctival Melanoma
Conjunctival melanoma is a malignant tumor of the conjunctiva, the mucous membrane covering the white of the eye and inner eyelids. It is typically pigmented (brown or black) but can also be nonpigmented (pink), which can make diagnosis more challenging. This tumor usually develops slowly over months to years and most commonly affects middle-aged to older adults, particularly those of Caucasian background. Although often painless, it can appear as a red, irritated eye due to associated vascularity.
A key feature is its association with primary acquired melanosis (PAM), a flat conjunctival pigmentation that can transform into melanoma over time—especially when atypia is present. Less commonly, conjunctival melanoma may arise from a pre-existing nevus. Clinically, the lesion appears as a nodular or elevated mass with prominent feeder blood vessels, sometimes surrounded by a “wreath” of dilated vessels. It can occur anywhere on the conjunctiva, including the limbus, bulbar surface, fornix, or caruncle, and may be unifocal or multifocal.
Despite its often slow growth, conjunctival melanoma is a serious condition with metastatic potential. It can invade locally into the eye or orbit and spread to regional lymph nodes, lungs, or brain. The overall risk of metastasis is approximately 25%, and mortality is a significant concern. Tumor size and location influence prognosis, with larger and more posterior lesions carrying higher risk.
Diagnosis is primarily clinical, supported by slit-lamp examination and detailed photographic documentation. It is critical to examine all conjunctival surfaces, including under the eyelids, and to assess for associated PAM. Imaging such as anterior segment OCT or MRI may be used if deeper invasion is suspected. Unlike many tumors, incisional biopsy is avoided due to the risk of tumor seeding; instead, management proceeds directly to excision.
The cornerstone of treatment is complete surgical excision using a “no-touch” technique, which minimizes manipulation of the tumor to prevent dissemination. This is combined with cryotherapy to surrounding tissue and treatment of any associated PAM. Additional therapies may include topical chemotherapy agents such as mitomycin C, 5-fluorouracil, or interferon for residual disease. In advanced cases with deeper invasion, radiotherapy or even orbital exenteration may be required.
Close, lifelong follow-up is essential due to the high risk of recurrence and metastasis. Patients are typically monitored every few months initially, then less frequently if stable. Systemic evaluation for metastatic disease—especially involving lymph nodes, lungs, and brain—is a critical component of care.
Prognosis varies. Recurrence rates are relatively high, and metastasis increases over time. However, many patients retain useful vision, especially with early detection and proper treatment. Complications can include vision loss, scarring, dry eye, diplopia, and, in severe cases, need for extensive surgical intervention.
Conjunctival melanoma is a malignant tumor of the conjunctiva, the mucous membrane covering the white of the eye and inner eyelids. It is typically pigmented (brown or black) but can also be nonpigmented (pink), which can make diagnosis more challenging. This tumor usually develops slowly over months to years and most commonly affects middle-aged to older adults, particularly those of Caucasian background. Although often painless, it can appear as a red, irritated eye due to associated vascularity.
A key feature is its association with primary acquired melanosis (PAM), a flat conjunctival pigmentation that can transform into melanoma over time—especially when atypia is present. Less commonly, conjunctival melanoma may arise from a pre-existing nevus. Clinically, the lesion appears as a nodular or elevated mass with prominent feeder blood vessels, sometimes surrounded by a “wreath” of dilated vessels. It can occur anywhere on the conjunctiva, including the limbus, bulbar surface, fornix, or caruncle, and may be unifocal or multifocal.
Despite its often slow growth, conjunctival melanoma is a serious condition with metastatic potential. It can invade locally into the eye or orbit and spread to regional lymph nodes, lungs, or brain. The overall risk of metastasis is approximately 25%, and mortality is a significant concern. Tumor size and location influence prognosis, with larger and more posterior lesions carrying higher risk.
Diagnosis is primarily clinical, supported by slit-lamp examination and detailed photographic documentation. It is critical to examine all conjunctival surfaces, including under the eyelids, and to assess for associated PAM. Imaging such as anterior segment OCT or MRI may be used if deeper invasion is suspected. Unlike many tumors, incisional biopsy is avoided due to the risk of tumor seeding; instead, management proceeds directly to excision.
The cornerstone of treatment is complete surgical excision using a “no-touch” technique, which minimizes manipulation of the tumor to prevent dissemination. This is combined with cryotherapy to surrounding tissue and treatment of any associated PAM. Additional therapies may include topical chemotherapy agents such as mitomycin C, 5-fluorouracil, or interferon for residual disease. In advanced cases with deeper invasion, radiotherapy or even orbital exenteration may be required.
Close, lifelong follow-up is essential due to the high risk of recurrence and metastasis. Patients are typically monitored every few months initially, then less frequently if stable. Systemic evaluation for metastatic disease—especially involving lymph nodes, lungs, and brain—is a critical component of care.
Prognosis varies. Recurrence rates are relatively high, and metastasis increases over time. However, many patients retain useful vision, especially with early detection and proper treatment. Complications can include vision loss, scarring, dry eye, diplopia, and, in severe cases, need for extensive surgical intervention.
0 Comments
